Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Coler, Rhea N ^a   Bertholet, Sylvie ^a,d   Moutaftsi, Magdalini ^a   Guderian, Jeff A ^a   Windish, Hillarie Plessner ^a   Baldwin, Susan L ^a   Laughlin, Elsa M ^a   Duthie, Malcolm S ^a   Fox, Christopher B ^a   Carter, Darrick ^a   Friede, Martin ^b   Vedvick, Thomas S ^a   Reed, Steven G ^a,c  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Immune Design Corp   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; CD40 ANTIGEN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CXCL1 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOPYRANOSYL LIPID ADJUVANT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 1; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MYXOVIRUS RESISTANCE PROTEIN; PHOSPHORYL LIPID A; PROTEIN KINASE INTERFERON INDUCIBLE DOUBLE STRANDED RNA DEPENDENT; RANTES; RECOMBINANT ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; LIPID A;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN ANALYSIS; QUALITATIVE RESEARCH; RNA ANALYSIS; TH1 CELL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY;

BACTERIA (MICROORGANISMS); MURINAE; NEGIBACTERIA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; LIPID A; MICE; TH1 CELLS;

EID: 79551551963     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016333     Document Type: Article

References (44)

1. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, et al. (1993) Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11: 293-306.
2. Wack A, Rappuoli R (2005) Vaccinology at the beginning of the 21st century. Curr Opin Immunol 17: 411-418.
3. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
4. Edelman R (2002) The development and use of vaccine adjuvants. Mol Biotechnol 21: 129-148.
5. Baldridge JR, Crane RT (1999) Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19: 103-107.
6. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, et al. (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2: 219-229.
7. Qureshi N, Kaltashov I, Walker K, Doroshenko V, Cotter RJ, et al. (1997) Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis. Journal of Biological Chemistry 272: 10594-10600.
8. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, et al. (2009) Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 4: e6465.
9. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, et al. (2009) The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 5: 475-482.
10. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28: 6581-6587.
11. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, et al. (2009) Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329-337.
12. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.
13. O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353-364.
14. Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109: 1519-1526.
15. Shen H, Tesar BM, Walker WE, Goldstein DR (2008) Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol 181: 1849-1858.
16. Brandenburg K, Wiese A (2004) Endotoxins: relationships between structure, function, and activity. Curr Top Med Chem 4: 1127-1146.
17. Darveau RP (1998) Lipid A diversity and the innate host response to bacterial infection. Curr Opin Microbiol 1: 36-42.
18. Caroff M, Karibian D, Cavaillon JM, Haeffner-Cavaillon N (2002) Structural and functional analyses of bacterial lipopolysaccharides. Microbes Infect 4: 915-926.
19. Alexander C, Rietschel ET (2001) Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7: 167-202.
20. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, et al. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75: 123-132.
21. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, et al. (2008) Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces 65: 98-105.
22. Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, et al. (2009) Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27: 3063-3071.
23. Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, et al. (2009) Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27: 5956-5963.
24. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, et al. (2009) Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
25. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5: e13677.
26. Raman VS, O'Donnell J, Bailor HR, Goto W, Lahiri R, et al. (2009) Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun 77: 5623-5630.
27. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, et al. (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205: 869-882.
28. Pulendran B, Ahmed R (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-863.
29. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, et al. (2008) Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 181: 7948-7957.
30. Akashi S, Nagai Y, Ogata H, Oikawa M, Fukase K, et al. (2001) Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol 13: 1595-1599.
31. Muroi M, Tanamoto K (2006) Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J Biol Chem 281: 5484-5491.
32. Rallabhandi P, Awomoyi A, Thomas KE, Phalipon A, Fujimoto Y, et al. (2008) Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J Immunol 180: 1139-1147.
33. Fox CB, Friede M, Reed SG, Ireton GC (2010) Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 53: 303-321.
34. Kim HM, Park BS, Kim JI, Kim SE, Lee J, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917.
35. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
36. Park BS, Song DH, Kim HM, Choi BS, Lee H, et al. (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
37. Walsh C, Gangloff M, Monie T, Smyth T, Wei B, et al. (2008) Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVa. J Immunol 181: 1245-1254.
38. Lu YC, Yeh WC, Ohashi PS (2008) LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151.
39. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, et al. (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2: 219-229.
40. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, et al. (2009) Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 284: 31982-31991.
41. Ohto U, Fukase K, Miyake K, Satow Y (2007) Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316: 1632-1634.
42. Kim HS, Han MS, Chung KW, Kim S, Kim E, et al. (2007) Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27: 321-333.
43. Flynn JL, Chan J (2001) Tuberculosis: latency and reactivation. Infect Immun 69: 4195-4201.
44. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, et al. (2006) Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 203: 1805-1815.